COVID-19 severity among patients with multiple sclerosis treated with cladribine: A systematic review and meta-analysis.
Mult Scler Relat Disord
; 68: 104156, 2022 Sep 05.
Article
in English
| MEDLINE | ID: covidwho-2007967
ABSTRACT
BACKGROUND:
The Coronavirus 19 pandemic has raised new relevant questions regarding the management of patients with multiple sclerosis (pwMS) treated with different immunosuppressive and immunomodulant drugs. In most COVID-19 outcomes analyses, due to the small available sample size, patients treated with cladribine were grouped with patients treated with other treatments.METHODS:
Three major databases (PubMed, Scopus and Web of Science) and the most recent MS congress libraries were searched for extracting original articles on COVID-19 and multiple sclerosis. The key inclusion criteria were the presence of data on pwMS treated with cladribine and with documented positivity for COVID-19. The quality of the included studies was evaluated using a modified version of the Dutch Cochrane center critical review checklist proposed by MOOSE. A common-effect meta-analysis was used for estimating the pooled proportion of patients with severe events (hospitalizations, pneumonia, ICU admissions and deaths) and heterogeneity was assessed by the I2 statistic.RESULTS:
13 articles were included in the analysis and the median quality of the articles reached a level of 4. The selected studies included 5138 patients with COVID-19, of whom 107 (2.1%) were treated with cladribine. Pooled estimates of hospitalization and death were 9.36% and 0% for patients treated with cladribine, 14.98% and 2.66% for pwMS under other treatments.CONCLUSION:
These results indicate that pwMS treated with cladribine are not at a greater risk of developing a severe form of COVID-19. REGISTRATION The protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO CRD42022329464).
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
/
Reviews
/
Systematic review/Meta Analysis
Language:
English
Journal:
Mult Scler Relat Disord
Year:
2022
Document Type:
Article
Affiliation country:
J.msard.2022.104156
Similar
MEDLINE
...
LILACS
LIS